Owlin adds Consumer Sentiment & Review Data to its offering in its journey to transform risk management for Payment Service Providers
12.9.2023 16:00:00 EEST | Business Wire | Press release
Owlin, a global leader in merchant and third-party risk solutions, proudly announces its next big step in advancing the fintech industry: a new Consumer Review Data feature, specifically designed for Risk teams within Payment Service Providers (PSPs). Operational excellence becomes more important than ever for PSPs and manual review processes are often costly, reactive and inefficient. Owlin's latest offering heralds a transformative shift towards proactive, cost-effective, and highly efficient risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912980645/en/
Owlin for Consumer Review Monitoring for Payment Service Providers (PSPs) (Photo: Business Wire)
One of the standout features of Owlin's Consumer Review Feature is its unparalleled ability to detect leading risk signals, such as signs of distress (e.g., delivery- or product issues) well ahead of bigger issues like a bankruptcy event. This capability provides PSPs with a significant advantage in proactively mitigating risk, preventing potential financial disasters, and safeguarding their operations and reputation.
Furthermore, Owlin's Consumer Review Feature is a significant advantage in the world of adverse media monitoring, helping improve merchant risk management. It builds upon Owlin's already world-class monitoring solution for PSPs and it gives PSPs the tools they need to stay competitive.
Key Features and Benefits:
- Real-time Feedback and Risk Alerts - Instantly gather consumer feedback and correlate it with advanced risk signals, alerting PSPs to potential risks well in advance.
- Advanced Analytics - Utilize AI-driven insights powered by large language models to gauge sentiment, track trends, and pinpoint areas requiring risk mitigation.
- Enhanced Engagement and Trust Building - Responsively address concerns, showcase negative reviews, risk mitigating actions, and fortify trust in the PSP ecosystem.
- In-depth Risk Profiles - Craft comprehensive risk profiles based on a blend of signals and consumer feedback, ensuring that risk management decisions are data-driven and merchant-centric.
Stefan Peekel, Chief Growth Officer at Owlin, remarks, “By integrating consumer review data into risk management practices, we're giving PSPs a comprehensive tool that's been absent in the industry. It's not just about enhancing services but also about fortifying them against threats. In essence we now equip PSPs with a magnifying glass and a map. While they get a detailed view of consumer sentiment on a merchant, they also see how signals interconnect, allowing them to preempt risks and capitalize on opportunities.’’
Dedicated to innovation, Owlin keeps pushing to redefine what is possible in the domain of risk management. With this latest consumer review offering Payment Service Providers are equipped with a new set of state of the art tools to manage risk effectively and build trust for merchants and consumers.
About Owlin
Owlin is an AI-driven Third Party Risk and Merchant Monitoring solution that helps businesses feed better and faster risk insights into daily risk management workflows in real time. Owlin applies AI and Natural Language Processing to provide valuable insights hidden in the data and ensures its users don’t get lost in the wealth of information by visualizing complex data in a simple and customizable interface.
For more information, visit https://owlin.com/solutions/consumer-review-monitoring/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912980645/en/
Contact information
Contact Owlin: Stefan Peekel, stefan@owlin.com, +1 201 932 4580
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom